Industry Diagnoses Need For R&D Incentives, Cites Regulatory Track Infection
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Without clear guidance from FDA on what it is looking for in anti-infective drug development, there isn't enough incentive for sponsors to continue R&D in the area, industry reps cautioned at the CAP public workshop.